| ×ת××××
|
Rheumatoid arthritis RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Psoriatic arthritis RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate. Ankylosing spondylitis RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. Atopic dermatitis RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Ulcerative colitis RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohnâs disease RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohnâs disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.Polyarticular juvenile idiopathic arthritisRINVOQ 15mg tablets is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.Limitations of Use RINVOQ 15 MG is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.Juvenile psoriatic arthritis RINVOQ 15 MG is indicated for the treatment of pediatric patients 2 years of age and older with active juvenile psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.Limitations of Use RINVOQ 15 MG is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine."
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 30/01/2020
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×תר××¤× ×ª×× ×ª× ×××פ×× ××רתר×××ס ר×××××××××ת (Rheumatoid arthritis) ××שר ×ת×××× ×ת×ש×ר×× ××שפ×ת ×-DMARDs ××× × × ×ספקת ×××תק××× ×× ×××: ×. ק×××ת ×¢××ת ×××קת פרק×× (RA-Rheumatoid Arthritis) פע××× ××ת×××ת ×ש×××©× ×ת×× ×××: 1. ×××× ××קת×ת (×××× ××× ×× ×¤×××ת) ××ר××¢× ×¤×¨×§×× ×××תר; 2. שק×עת ×× ×× CRP ×××ר××× ××× ×ר×× ××××¤× ×ש××¢××ª× (××ת×× ×××× ×××××); 3. ש×× ×××× ××פ××× ××× ×-RA ×צ××××× ×¨× ××× ×©× ×פרק×× ×× ×××¢××; 4. פ×××¢× ×ª×¤×§×××ת ×××××רת ×××××× ×ש××¢×ת×ת ×תפק××× ×××××××× ×©× ××××× ××פע××××ª× ××¢××××. ×. ×××ר ××צ×× ×××פ×× ×תר×פ×ת ×ש××××ת ××שפ×ת ×-NSAIDs ××תר×פ×ת ×ש××××ת ××שפ×ת ×-DMARDs. ××¢× ××× ×× ××××ר ××צ×× ×××פ×× ×××¢×ר ת×××× ×§××× ×ת ×××ר ××פ×× ×§× ×¨×ש×× ×תר×פ×ת ×× ×× ××קת××ת ××שפ×ת ×-NSAIDs ×××פ×× ×§× ×©× × ×-3 תר×פ×ת ×פ××ת ××שפ×ת ×-DMARDs ש××ת ××× ×ת××רקס××, ×××©× 3 ×××ש×× ×¨×¦×פ×× ×פ××ת. ×. ×××פ×× ××× ×ª× ×××ש×ר ××××× ×ר××××××××××
|
30/01/2020
|
ר××××××××××
|
TOFACITINIB, BARICITINIB, UPADACITINIB, CERTOLIZUMAB PEGOL, TOCILIZUMAB, SARILUMAB, ABATACEPT, ETANERCEPT, INFLIXIMAB
|
Rheumatoid arthritis |
|
| ××קת ×פרק×× ×¤×¡×ר××××ת פע××× ××תק××ת, ××§× ××פ×× ×©× × ××××× ×××ר ××צ×× ××פ×× ×ת×ש×ר ××שפ×ת ××¢××× TNF.
|
03/02/2022
|
ר×××××××××× |
|
Psoriatic arthritis |
|
| ×××× ×תרפ×× ×××פ×× ×-Atopic dermatitis ××ר×ת ××××¨× ××× ×× ×ת ×¢× ×§×©× (××ת×× ×סק×ת IGA ×ר×× 3 ×× 4) ×××××× ×©××××ª× ×× × ×©××ת ×× ×¢×××¨× ×§×××ת ××ר××ת × ×× ×××ר ××פ×× ×ק××× ××§× ××פ×× ×¡×ס××× ××× ×פ××ת (××¢× ××× ×× ××פ×× ×¡×ס××× ×××©× ×××× ×××× - Cyclosporine, Azathioprine, Mycophenolate, Methotrexate), ×©× ×ש×× ×× ××× ×פ××ת 3 ×××ש××, ×××¢× ××קר×× ×©× ××××¨× ×ש××¢×ת×ת ×××¦× ××××× ×× ××××× ××תפת×× ×ª×פע×ת ××××× ×©××× × ××פשר×ת ×××©× ××פ××. ××××× ××××ª× ×××× ××××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Dupilumab, Upadacitinib. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×רפ××ת ×¢×ר ×××× ×× ××××× ×××ר××× ×××××× ×××××× ×§××× ×ת.
|
03/02/2022
|
×¢×ר ×××× |
|
Atopic dermatitis, ×××פ×ק ×ר×××××ס |
|
| ×× ×§×××××× × ×¡×¤×× ××××××ס (Ankylosing spondylitis), ××§× ××פ×× ×©× × ××××× ×××ר ××צ×× ××פ×× ×ת×ש×ר ××שפ×ת ××¢××× TNF.
|
03/02/2022
|
ר×××××××××× |
|
Ankylosing spondylitis |
|
| ××פ×× ×-Ulcerative colitis ××ר×ת ××××¨× ××× ×× ×ת ×¢× ×§×©× ××§× ××פ×× ×©× × ××××× ×××ר ××צ×× ××פ×× ×ת×ש×ר ×××××××.
|
01/02/2023
|
×ס×ר××× ×ר×××××× |
|
|
| ×××× ×תרפ×× ×××פ×× ×-Atopic dermatitis ××ר×ת ××××¨× ××× ×× ×ת ×¢× ×§×©× (××ת×× ×סק×ת IGA ×ר×× 3 ×× 4) ×××××× ×©××××ª× ×× × ×©××ת ×× ×¢×××¨× ×§×××ת ××ר××ת × ×× ×××ר ××פ×× ×ק××× ××§× ××פ×× ×¡×ס××× ××× ×פ××ת (××¢× ××× ×× ××פ×× ×¡×ס××× ×××©× ×××× ×××× â Cyclosporine, Azathioprine, Mycophenolate, Methotrexate), ×©× ×ש×× ×× ××× ×פ××ת 3 ×××ש××, ×××¢× ××קר×× ×©× ××××¨× ×ש××¢×ת×ת ×××¦× ××××× ×× ××××× ××תפת×× ×ª×פע×ת ××××× ×©××× × ××פשר×ת ×××©× ××פ××. ×××פ×× ×× ××× ×ª× ×ש×××× ×¢× Dupilumab ×× Abrocitinib. ××××× ××××ª× ×××× ××××× ×××× ×ק×× ××פ×× ×âDupilumab , ××××ת ××©×ª× ×תר×פ×ת â Upadacitinib, Abrocitinib. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×רפ××ת ×¢×ר ×××× ×× ××××× ×××ר××× ×××××× ×××××× ×§××× ×ת.
|
01/02/2023
|
×¢×ר ×××× |
|
Atopic dermatitis, ×××פ×ק ×ר×××××ס |
|
| ×××× ×תרפ×× ×××פ×× ×-Atopic dermatitis ××ר×ת ××××¨× ××× ×× ×ת ×¢× ×§×©× (××ת×× ×סק×ת IGA ×ר×× 3 ×× 4) ×××××× ×©××××ª× ×× × ×©××ת ×× ×¢×××¨× ×§×××ת ××ר××ת × ×× ×××ר ××פ×× ×ק××× ××§× ××פ×× ×¡×ס××× ××× ×פ××ת (××¢× ××× ×× ××פ×× ×¡×ס××× ×××©× ×××× ×××× - Cyclosporine, Azathioprine, Mycophenolate, Methotrexate), ×©× ×ש×× ×× ××× ×פ××ת 3 ×××ש××, ×××¢× ××קר×× ×©× ××××¨× ×ש××¢×ת×ת ×××¦× ××××× ×× ××××× ××תפת×× ×ª×פע×ת ××××× ×©××× × ××פשר×ת ×××©× ××פ××. ×××פ×× ×× ××× ×ª× ×ש×××× ×¢× Dupilumab ×× Abrocitinib ×× Baricitinib. ××××× ××××ª× ×××× ××××× ×××× ×ק×× ××פ×× ×âDupilumab , ××××ת ×ש××ש ×תר×פ×ת â Upadacitinib, Abrocitinib, Baricitinib. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×רפ××ת ×¢×ר ×××× ×× ××××× ×××ר××× ×××××× ×××××× ×§××× ×ת.
|
×¢×ר ×××× |
|
×××פ×ק ×ר×××××ס, Atopic dermatitis |
|
|
ש×××ש ×ס×
-
|
| ×ס×רת ××××× ×ס×
×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- ××פ×× ××רתר×××ס ר×××××××××ת (Rheumatoid arthritis) ××שר ×ת×××× ×ת×ש×ר×× ××שפ×ת ×-DMARDs ××× × × ×ספקת, ××פ××£ ××× ×××:
- ק×××ת ×¢××ת ×××קת פרק×× (RA-Rheumatoid Arthritis) פע××× ××ת×××ת ×ש×××©× ×ת×× ×××:
- ×××× ××קת×ת (×××× ××× ×× ×¤×××ת) ××ר××¢× ×¤×¨×§×× ×××תר
- שק×עת ×× ×× CRP ×××ר××× ××× ×ר×× ××××¤× ×ש××¢××ª× (××ת×× ×××× ×××××)
- ש×× ×××× ××פ××× ××× ×-RA ×צ××××× ×¨× ××× ×©× ×פרק×× ×× ×××¢××
- פ×××¢× ×ª×¤×§×××ת ×××××רת ×××××× ×ש××¢×ת×ת ×תפק××× ×××××××× ×©× ××××× ××פע××××ª× ××¢××××.
- ×××ר ××צ×× ×××פ×× ×תר×פ×ת ×ש××××ת ××שפ×ת ×-NSAIDs ××תר×פ×ת ×ש××××ת ××שפ×ת ×-DMARDs.
××¢× ××× ×× ××××ר ××צ×× ×××פ×× ×××¢×ר ת×××× ×§××× ×ת ×××ר ××פ×× ×§× ×¨×ש×× ×תר×פ×ת ×× ×× ××קת××ת ××שפ×ת ×-NSAIDs ×××פ×× ×§× ×©× × ×-3 תר×פ×ת ×פ××ת ××שפ×ת ×-DMARDs, ש××ת ××× ×ת××רקס××, ×××©× 3 ×××ש×× ×¨×¦×פ×× ×פ××ת.
- ×××פ×× ××× ×ª× ×××ש×ר ר××¤× ××××× ×ר××××××××××
- ×××× ×תרפ×× ×××פ×× ×-Atopic dermatitis ××ר×ת ××××¨× ××× ×× ×ת ×¢× ×§×©× (××ת×× ×סק×ת IGA ×ר×× 3 ×× 4) ×××××× ×©××××ª× ×× × ×©××ת ×× ×¢×××¨× ×§×××ת ××ר××ת × ×× ×××ר ××פ×× ×ק××× ××§× ××פ×× ×¡×ס××× ××× ×פ××ת (Cyclosporine, Azathioprine, Mycophenolate, Methotrexate).
××¢× ××× ×× ××פ×× ×¡×ס××× ×××©× ×××× ×××× Cyclosporine, Azathioprine, Mycophenolate, Methotrexate, ×©× ×ש×× ×× ××× ×פ××ת 3 ×××ש××, ×××¢× ××קר×× ×©× ××××¨× ×ש××¢×ת×ת ×××¦× ××××× ×× ×× ×תפת×× ×ª×פע×ת ××××× ×©××× × ××פשר×ת ×××©× ××פ××.
×××פ×× ×× ××× ×ª× ×ש×××× ×¢× Dupilumab ×× Abrocitinib ×× Baricitinib.
××××× ××××ª× ×××× ××××× ×××× ×ק×× ××פ×× ×-Dupilumab ××××ת ×ש××ש ×תר×פ×ת - Upadacitinib, Abrocitinib, Baricitinib.
××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×רפ××ת ×¢×ר ×××× ×× ××××× ×××ר××× ×××××× ×××××× ×§××× ×ת
- ××קת ×פרק×× ×¤×¡×ר××××ת פע××× ××תק××ת, ××§× ××פ×× ×©× × ××××× ×××ר ××צ×× ××פ×× ×ת×ש×ר ××שפ×ת ××¢××× TNF
- ×× ×§×××××× × ×¡×¤×× ××××××ס (Ankylosing spondylitis), ××§× ××פ×× ×©× × ××××× ×××ר ××צ×× ××פ×× ×ת×ש×ר ××שפ×ת ××¢××× TNF
- ××פ×× ×-Ulcerative colitis ××ר×ת ××××¨× ××× ×× ×ת ×¢× ×§×©× ××§× ××פ×× ×©× × ××××× ×××ר ××צ×× ××פ×× ×ת×ש×ר ×××××××
|
|
